Journal
CANADIAN JOURNAL OF CARDIOLOGY
Volume 28, Issue 6, Pages 706-711Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cjca.2012.04.014
Keywords
-
Categories
Funding
- Heart and Stroke Foundation of Ontario [NA7313]
- Heart and Stroke Foundation
- Summer Research Training Program at Schulich School of Medicine and Dentistry
- Canadian Institutes of Health Research (CIHR)
- Heart & Stroke Foundation of Canada
- National Institutes of Health (NIH)
- Merck
- Novartis
- Boehringer-Ingelheim
Ask authors/readers for more resources
Background: In animal models, aldosterone has adverse cardiac and vascular effects independent of blood pressure, and these are ameliorated by spironolactone or eplerenone (mineralocorticoid receptor antagonists). Both agents reduce mortality in human systolic heart failure. We studied the effect of plasma aldosterone on human carotid atherosclerosis. Methods: The effect of plasma aldosterone on progression of carotid total plaque area (TPA) was studied using multiple linear regression, with variables that have previously been shown to maximally explain TPA variation (age, sex, total cholesterol, systolic blood pressure, diabetes, smoking, and medication for cholesterol and systolic blood pressure). Results: Complete data were available in 848 patients with progression of plaque from baseline to the following year and in 571 for progression in the second year. In stepwise linear regression, plasma aldosterone was the only independent predictor of plaque progression in the first year (P = 0.005) and in the second year (P = 0.001). Conclusions: Plasma aldosterone is associated with progression of atherosclerosis. We are now planning to test the effects of mineralocorticoid receptor antagonism on plaque progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available